Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 14;10(10):2131.
doi: 10.3390/jcm10102131.

Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT

Affiliations
Review

Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT

Meritxell Molla et al. J Clin Med. .

Abstract

The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians' factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments.

Keywords: ablation; colorectal cancer; liver metastases; lung metastases; oligometastasis; stereotactic body radiation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

Figures

Figure 1
Figure 1
Lung metastases from CRC. Planning treatment: Dose: 60 Gy in 3 fractions. DBE: 150 Gy.
Figure 2
Figure 2
Liver metastases from CRC. Planning treatment. Dose: 55 Gy in 5 fractions. DBE: 116 Gy.
Figure 3
Figure 3
Treatment algorithm in limited liver and lung CRC metastases.

Similar articles

Cited by

References

    1. Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J.H., Aderka D., Aguilar E.A., Bardelli A., Benson A., Bodoky G., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016;27:1386–1422. doi: 10.1093/annonc/mdw235. - DOI - PubMed
    1. Andersen I.R., Thorup K., Jepsen B.N., Mortensen F.V., Nielsen D.T., Rasmussen F. Dynamic contrast-enhanced computed tomography in the treatment evaluation of patients with colorectal liver metastases treated with ablation: A feasibility study. Acta Radiol. 2019;60:936–945. doi: 10.1177/0284185118806661. - DOI - PubMed
    1. Palussière J., Catena V., Buy X. Percutaneous thermal ablation of lung tumors–Radiofrequency, microwave and cryotherapy: Where are we going? Diagn. Interv. Imaging. 2017;98:619–625. doi: 10.1016/j.diii.2017.07.003. - DOI - PubMed
    1. Ahmed M., Liu Z., Afzal K.S., Weeks D., Lobo S.M., Kruskal J.B., Lenkinski R.E., Goldberg S.N. Radiofrequency Ablation: Effect of Surrounding Tissue Composition on Coagulation Necrosis in a Canine Tumor Model. Radiology. 2004;230:761–767. doi: 10.1148/radiol.2303021801. - DOI - PubMed
    1. Ihara H., Gobara H., Hiraki T., Mitsuhashi T., Iguchi T., Fujiwara H., Matsui Y., Soh J., Toyooka S., Kanazawa S. Radiofrequency Ablation of Lung Tumors Using a Multitined Expandable Electrode: Impact of the Electrode Array Diameter on Local Tumor Progression. J. Vasc. Interv. Radiol. 2016;27:87–95. doi: 10.1016/j.jvir.2015.07.025. - DOI - PubMed